Abstract
Cancer-initiating stem cells (CISC) represent a minor subpopulation of heterogeneous breast cancer. CISC are responsible for the acquired resistance to conventional chemoendocrine therapy and eventual relapse observed in patients with breast cancer. Certain molecular subtypes of clinical breast cancer that exhibit differential expression of genes coding for hormone and growth factor receptors differ in their response to conventional chemoendocrine therapy and targeted therapeutic inhibitors. Thus, the development of reliable cell culture models for CISC may provide a valuable experimental approach for the study of stem cell-targeted therapy for the treatment of breast cancer. The present study utilized optimized cell culture systems as experimental models for different molecular subtypes of clinical breast cancer, including luminal A, human epidermal growth factor receptor (HER)-2-enriched and triple negative breast cancer. Biomarker end points, including control of homeostatic growth, cancer risk and drug resistance, were quantitatively analyzed in the selected models. The results of the analyses indicated that, compared with the non-tumorigenic controls, the cell models representing the aforementioned molecular subtypes of cl...Continue Reading
References
May 1, 1993·Steroids·A SutoN T Telang
Feb 12, 1998·Proceedings of the Society for Experimental Biology and Medicine·N T TelangJ Fishman
Sep 25, 1998·Journal of the National Cancer Institute·B FisherN Wolmark
Sep 13, 2001·Proceedings of the National Academy of Sciences of the United States of America·T SørlieA L Børresen-Dale
Dec 12, 2003·Nature Reviews. Cancer·Stephen R D Johnston, Mitch Dowsett
Apr 2, 2005·Nature Reviews. Cancer·Michael DeanSusan Bates
Oct 21, 2005·The New England Journal of Medicine·Edward H RomondNorman Wolmark
Mar 3, 2007·The Lancet Oncology·Susan CleatorR Charles Coombes
Jul 25, 2007·Annual Review of Cell and Developmental Biology·Neethan A LoboMichael F Clarke
Sep 14, 2007·Nature Reviews. Cancer·John Stingl, Carlos Caldas
Jun 11, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tomonori TaneiShinzaburo Noguchi
Jun 19, 2009·Nature Reviews. Cancer·José Baselga, Sandra M Swain
Aug 25, 2009·Nature Reviews. Cancer·Elizabeth A Musgrove, Robert L Sutherland
Jul 28, 2011·OncoTargets and Therapy·Pham Van PhucPhan Kim Ngoc
Jun 23, 2012·Science·Katrin HoffmeyerRolf Kemler
Aug 24, 2012·Cancer Discovery·Yasir H IbrahimJosé Baselga
Dec 22, 2012·Nature Reviews. Cancer·Jamie N Anastas, Randall T Moon
Jan 1, 2014·Nutrition and Cancer·Nitin TelangGeorge Y C Wong
Feb 11, 2015·Cancer Research·Gyu-Beom JangJeong-Seok Nam
Citations
Apr 16, 2013·PloS One·Qiang LinPing Zhang
Mar 22, 2018·International Journal of Molecular Sciences·Benjamin B KastenDonald J Buchsbaum
Aug 19, 2017·Biomedical Reports·Nitin Telang
Sep 15, 2018·Oncology Letters·Nitin Telang
Feb 13, 2018·Oncology Letters·Nitin Telang
Nov 30, 2016·Oncology Letters·Nitin TelangGeorge Wong
Jan 19, 2018·Oncology Letters·Yu WangZhitu Zhu
Apr 30, 2017·Oncology Letters·Nitin T TelangGeorge Y C Wong
Dec 8, 2020·BioMed Research International·Xiaoling LengFucheng Ma